Tag: Liver Disease: Misc.
GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV
Semaglutide linked to declines in intrahepatic triglycerides for people with HIV with metabolic-associated steatotic liver disease
FDA Approves Rezdiffra for Nonalcoholic Steatohepatitis
Drug was approved on an 'accelerated' schedule due to pressing medical need
NASH Resolution Increased, Improvement of Fibrosis Seen With Resmetirom
Resmetirom 80 mg and 100 mg better than placebo for patients with NASH and fibrosis stage F1B, F2, F3
Women Have Greater Mortality With Alcohol-Related Liver Disease
Findings persist across steatotic liver disease phenotypes
GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease
For patients with chronic liver disease and type 2 diabetes, GLP1 agonist initiators associated with lower risk for major adverse liver outcomes
Guidelines Developed for Management of Alcohol-Associated Liver Disease
Multidisciplinary integrated care model with hepatology, addiction medicine providers, social workers should be promoted
Study Looks at Alcohol Intake, Mortality Link in Steatotic Liver Disease
For those with low risk of advanced fibrosis, hazard ratio was increased with consumption of 7.4 g/day or more
Prevalence of NAFLD Set to Increase to 34.3 Percent in 2050
NAFLD set to cause 19,300 new cases of HCC and 4,200 new cases of liver transplant per year by 2050
High-Risk Patients Awaiting Liver Transplant Benefit Most From Living Donors
Benefit was most evident in wait-listed cirrhosis patients with moderate-to-severe frailty
Sarcopenia Worsens Liver Transplant Outcomes for Patients With Cirrhosis
Sarcopenia tied to longer intensive care unit stay, more major complications, higher postoperative mortality
